| Literature DB >> 30042294 |
Witold Nawrot1, Kamila Drzozga2, Sylwia Baluta3, Joanna Cabaj4, Karol Malecha5.
Abstract
The clinical applications of sensing tools (i.e., biosensors) for the monitoring of physiologically important analytes are very common. Nowadays, the biosensors are being increasingly used to detect physiologically important analytes in real biological samples (i.e., blood, plasma, urine, and saliva). This review focuses on biosensors that can be applied to continuous, time-resolved measurements with fluorescence. The material presents the fluorescent biosensors for the detection of neurotransmitters, hormones, and other human metabolites as glucose, lactate or uric acid. The construction of microfluidic devices based on fluorescence uses a variety of materials, fluorescent dyes, types of detectors, excitation sources, optical filters, and geometrical systems. Due to their small size, these devices can perform a full analysis. Microfluidics-based technologies have shown promising applications in several of the main laboratory techniques, including blood chemistries, immunoassays, nucleic-acid amplification tests. Of the all technologies that are used to manufacture microfluidic systems, the LTCC technique seems to be an interesting alternative. It allows easy integration of electronic and microfluidic components on a single ceramic substrate. Moreover, the LTCC material is biologically and chemically inert, and is resistant to high temperature and pressure. The combination of all these features makes the LTCC technology particularly useful for implementation of fluorescence-based detection in the ceramic microfluidic systems.Entities:
Keywords: LTCC technology; biological samples; biosensors; fluorescence; sensors
Mesh:
Substances:
Year: 2018 PMID: 30042294 PMCID: PMC6111579 DOI: 10.3390/s18082357
Source DB: PubMed Journal: Sensors (Basel) ISSN: 1424-8220 Impact factor: 3.576
Figure 1Fluorescent strategy to detect hormones.
Fluorescence-based biosensors for hormones determination.
| Biomarker | Sensing Platform | Transduction Type | LOD | References |
|---|---|---|---|---|
| 17β-estradiol | Aptamers specific for 17β-estradiol | Evanescent Wave | 2.1 nM | [ |
| 17β-estradiol | anti-E2 antibody | Change in fluorescence intensity | 6.37 × 10−6 ng mL−1 | [ |
| 17β-estradiol | Fluorescein | Change in fluorescence intensity | 30 nM | [ |
| Estriol | Graphene oxide/estriol complex | FRET | 1.3 nM | [ |
| Testosterone | Anti-testosterone antibody | TIRF | 0.2 ng L−1 | [ |
| Insulin | Aptamers specific for insulin | FRET | 0.72 pM | [ |
| Insulin | Anti-insulin antibody | FRET | 3.0 × 10−6 ng/mol | [ |
Figure 2Methods for fluorescence determination using biosensors (general scheme).
Figure 3A general scheme for quenching the high fluorescence of nanoparticles by dopamine (DA).
Fluorescence-based biosensors and sensors for neurotransmitters determination.
| Biomarker | Sensing Platform | Transduction Type | LOD | References |
|---|---|---|---|---|
| DA | GQDs/pDA complex | FRET | 8 nM | [ |
| DA | Functionalized-CuInS2 QDs | FI | 200 nM | [ |
| 5HT | APTES-functionalized surface-assembly of Ag@mSiO2 | Interferometry | 84 fM | [ |
| 5HT | Ehrlich’s reagent-5HT complex | Spectrophotometry | 2.3 μM | [ |
| DA | dithienotetraphenylsilane/laccase GQDs/pDA complex | FRET | 80 nM | [ |
| DA | CdSe/ZnS QDs/A | FI | 29.3 nM | [ |
Figure 4Fluorescent strategy to detect lactate with lactate dehydrogenase (LDH).
Figure 5Fluorescent strategy to detect uric acid using lactate uricase and horseradish peroxidase (HRP).
Fluorescence-based biosensors for exemplary metabolites determination.
| Biomarker | Sensing Platform | Transduction Type | LOD | References |
|---|---|---|---|---|
| Lactate | LDH/medical capillary | Change in fluorescence intensity | 0.45 mM | [ |
| Lactate | LDH/optical fiber | Change in fluorescence intensity | 20 μM | [ |
| Uric acid | QDs/uricase/HRP | FRET | 125 μM | [ |
| Uric acid | UCNPs/uricase | IFE | 6.7 μM | [ |
| Glucose | MIL-53(Fe)/GOx | Change in fluorescence intensity | 8.44 × 10−9 mol L−1 | [ |
| Glucose | CdSe/ZnS QDs/concanavalin A | FRET | - | [ |
| Glucose | RDC/SNS/GOx | Change in fluorescence intensity | 1.2 nM | [ |
Figure 6The two-component microfluidic system for fluorescence measurements: the microfluidic chip (left) and base station (right).